Gluco-A 100 mg

Indication:

Gluco-A 100 mg is indicated for the treatment of-

Type 2 Diabetes Mellitus (T2DM) Monotherapy: Indicated as an adjunct to diet and exercise to manage hyperglycemia in patients whose blood glucose cannot be controlled by lifestyle modifications alone.
Combination Oral Therapy: Indicated in combination with sulfonylureas, metformin, or insulin when diet, exercise, and a single oral antidiabetic agent do not result in adequate glycemic control.
Impaired Glucose Tolerance (Off-Label / Prophylactic): Used in patients with prediabetes to delay or prevent the progression to overt Type 2 Diabetes.

Dogase & Adminstration:

Adult Dosage (Standard Protocol):

Initial Dose: 25 mg orally three times daily. Alternatively, to minimize GI side effects, therapy can be started at 25 mg once daily and titrated up gradually to three times daily.
Maintenance Titration: After 4 to 8 weeks of therapy, the dose can be increased to 50 mg three times daily. If necessary, it can be further titrated up to a maximum dose based on patient response and weight.
Maximum Dose: For patients weighing less 60 kg, the maximum dose is 50 mg three times daily. For patients weighing > 60 kg, the maximum dose is 100 mg three times daily.

Pediatric Dosage:

Child / Adolescent: Safety, efficacy, and appropriate dosage profiles in pediatric populations under 18 years of age have not been established. Use is generally not recommended unless strictly supervised by a pediatric endocrinologist in specialized clinical conditions.

Administration Guidelines:

Strict Ingestion Timing: Must be taken orally at the start (with the very first bite) of each main meal.
Ingestion Method: Tablets should be swallowed whole with a small amount of water or chewed along with the first few mouthfuls of food. Taking it after a meal diminishes its therapeutic efficacy entirely.

Renal Impairment Adjustments:

Mild to Moderate Impairment: Use caution; monitor renal function.
Severe Impairment (Creatinine Clearance < 25 : Contraindicated. Do not use. ''রেজিস্ট্রার চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন'' Pharmacology: Mechanism of Action (MOA): Acarbose acts as a competitive, reversible inhibitor of membrane-bound intestinal alpha-glucosidase enzymes (including sucrase, maltase, glucoamylase, and dextrinase) located in the brush border of the small intestine. It also weakly inhibits pancreatic alpha-amylase. By blocking these enzymes, it delays the hydrolytic breakdown of complex carbohydrates, oligosaccharides, and disaccharides into absorbable monosaccharides (like glucose). Consequently, glucose absorption is prolonged, flattening the postprandial blood glucose curve. Pharmacodynamics: Acarbose does not enhance insulin secretion, nor does it increase peripheral insulin sensitivity. Because its mechanism is localized to the gastrointestinal tract, it reduces postprandial hyperglycemia without causing hyperinsulinemia. This localized action prevents direct systemic hypoglycemic episodes when used as monotherapy. However, the delivery of undigested carbohydrates into the large intestine results in colonic bacterial fermentation, which underpins its primary gastrointestinal effects. Pharmacokinetics: Absorption: Acarbose acts locally within the GI tract and exhibits very low systemic absorption. Less than 1% to 2% of the active, unchanged drug enters the systemic circulation. Metabolism: It is metabolized exclusively within the gastrointestinal tract, primarily by intestinal bacteria and digestive enzymes, into at least 13 metabolized derivatives. Elimination: The absorbed systemic fraction is excreted via the kidneys through urine, while the unabsorbed active drug is eliminated via feces. The elimination half-life of the systemic absorbed fraction is approximately 2 hours. Side Effects: Very Common (>10%): Flatulence (gas), abdominal rumbling (borborygmi), abdominal pain, and loose stools/diarrhea due to carbohydrate fermentation in the colon.
Serious: Asymptomatic elevations in liver transaminases (ALT/AST), which are reversible upon discontinuation. Rarely, fulminant hepatitis or ileus.

Drug Interaction:
Digestive Enzymes & Adsorbents: Antacids, charcoal adsorbents, and intestinal enzyme preparations (e.g., amylase, pancreatin) may reduce the therapeutic effect of Acarbose. Avoid concurrent use.
Digoxin: Acarbose can interfere with the bioavailability of Digoxin, leading to reduced serum Digoxin levels. Monitor Digoxin levels closely.
Treatment of Hypoglycemia Note: If Acarbose is combined with insulin or sulfonylureas and hypoglycemia occurs, oral sucrose (cane sugar) must not be used because Acarbose blocks its breakdown. Pure oral glucose (dextrose) must be administered instead.

Pregnancy & Lactation:
Pregnancy: Category B. Clinical data on pregnant women are highly limited. Acarbose is not recommended during pregnancy; insulin remains the standard choice.
Lactation: Acarbose is excreted in the milk of lactating animals in small quantities. Because safety in human infants is unverified, it should not be administered to breastfeeding mothers.

Over Dosage:

When Acarbose is taken in excess with carbohydrate-containing foods/drinks, an overdose can cause severe flatulence, diarrhea, and severe abdominal distress. Treatment involves withholding carbohydrate intake for a few hours and providing symptomatic support. Avoid treating with standard sugar.

Therapeutic Class:

Antidiabetic / Alpha-Glucosidase Inhibitor

Storage Conditions:

Store below at 30°C  temperature in a dry place. Away from light and out of reach of children. Do not use the medication after its expiration date.